SCYNEXIS

SCYNEXIS (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. Our lead product candidate, ibrexafungerp (formerly known as SCY-078), is a broad-spectrum intravenous/oral antifungal agent representing a novel therapeutic class. It is currently under regulatory review for the treatment of vaginal yeast infections, also known as vulvovaginal candidiasis (VVC), and is in late-stage development for treating life-threatening fungal infections in hospitalized patients. The SCYNEXIS team possesses deep expertise in anti-infective drug development and marketing, which can be leveraged to advance ibrexafungerp from clinical development to commercialization.